TM Owner Boehringer Ingelheim
Praxbind 2.5g/50mL (50mg/mL) per vial Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Praxbind 2.5 g/50 mL solution for injection or infusion contains idarucizumab, a specific reversal agent for dabigatran (marketed as Pradaxa), a direct-acting oral anticoagulant.
- Praxbind rapidly and completely neutralizes the anticoagulant effect of dabigatran in adults who need emergency surgery or an urgent procedure, or who have life-threatening or uncontrolled bleeding while taking dabigatran.
- It has no effect on other anticoagulants such as warfarin, other direct oral anticoagulants, or heparins.
- Praxbind is a specialist, hospital-administered medicine given only by a healthcare professional in an emergency or acute-care setting; it is never self-administered or kept at home.
- It is approved in both the United States (FDA) and the European Union (EMA) under the same brand name, Praxbind, and the same indication.
Side Effects
- In clinical studies, Praxbind was generally well tolerated; the most common reactions were headache in healthy volunteers and constipation and nausea in treated patients.
- Because Praxbind removes the anticoagulant effect of dabigatran, the most important risk is thromboembolism, meaning blood clots such as stroke, heart attack or deep vein thrombosis, if the underlying condition that required anticoagulation is not promptly managed; anticoagulation is usually restarted as soon as it is medically safe to do so.
- Coagulation test results can rise again 12 to 24 hours after the dose in some patients, and a second 5 g dose may be given if bleeding continues or re-anticoagulation is needed urgently.
- Hypersensitivity reactions, including rare serious allergic reactions, can occur, and the infusion is stopped immediately if this happens.
- Praxbind has no boxed warning on the current US or EU label.
- Report any signs of an allergic reaction or new clot symptoms to the treating team right away.
Precautions & Warnings
- Praxbind contains sorbitol; people with rare hereditary fructose intolerance should not receive it unless the potential benefit clearly outweighs the risk, and should be monitored closely.
- Because reversing dabigatran removes its anticoagulant protection, patients remain at risk of the thrombotic events their anticoagulant was treating or preventing, so resumption of anticoagulation is considered as soon as clinically appropriate.
- Praxbind is given only by intravenous infusion or injection in a hospital or emergency setting by trained healthcare staff; it is not for home use and there is no oral or subcutaneous form.
- There are no absolute contraindications listed on the label.
- Praxbind does not affect other anticoagulants and should not be used to reverse anything other than dabigatran.
- Use during pregnancy or breastfeeding should be discussed with the treating team, as this is an emergency medicine used based on clinical need.
- No dose adjustment is required for renal or hepatic impairment.
Avoid Interactions
- Praxbind has not been shown to interact with the coagulation factor concentrates, antifibrinolytic agents or other blood products sometimes given during emergency bleeding management, and in vitro data indicate its ability to bind and neutralize dabigatran is not affected by these agents.
- It specifically reverses dabigatran only; it does not reverse or interact with warfarin, other vitamin K antagonists, other direct oral anticoagulants such as apixaban or rivaroxaban, or heparins, so these should be managed separately if present.
- Because Praxbind is used in emergencies, the treating team reviews all other medicines the patient is taking, including antiplatelet drugs and any other anticoagulants, when deciding on further treatment.
- Praxbind is administered as two consecutive infusions or bolus injections; the two vials should not be mixed with other medicines in the same line, and standard aseptic and pharmacy compatibility practices apply when handling this medicine.
References
Frequently Asked Questions
Praxbind (idarucizumab) rapidly reverses the blood-thinning effect of dabigatran (Pradaxa) in adults who need emergency surgery or an urgent procedure, or who have life-threatening or uncontrolled bleeding. It only reverses dabigatran, not other anticoagulants like warfarin.
Praxbind is given only in hospital, by a healthcare professional, as two 2.5 g intravenous infusions or injections given back-to-back, for a total 5 g dose. You cannot take it at home or by mouth; it is used only in emergencies.
Praxbind is generally well tolerated; headache, constipation and nausea are the most commonly reported effects. Its main risk is blood clots, since removing dabigatran's anticoagulant effect can allow clotting problems to return; the team restarts anticoagulation as soon as it is safe.
No. Praxbind carries no FDA or EU boxed warning. The main precaution is that reversing dabigatran removes its anticoagulant protection, so there is a risk of thrombosis (clots) if anticoagulation is not restarted promptly once the bleeding or procedure is managed.
A healthcare professional gives two 2.5 g doses of Praxbind, one after the other, each as a short infusion or a rapid injection. You are monitored throughout for allergic reactions and bleeding control. Coagulation tests may be repeated afterward, since values can rise again after 12-24 hours.
Yes. A second 5 g dose of Praxbind can be given if uncontrolled or life-threatening bleeding continues, or if another emergency procedure is needed. This is based on limited clinical data but is included in the prescribing information for these situations.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
